Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,812,434 papers from all fields of science
Search
Sign In
Create Free Account
caplacizumab
A humanized, bivalent anti-von Willebrand factor (VWF) nanobody, with potential anti-platelet and anti-thrombotic activities. Upon administration…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
ALX-0081
Broader (1)
Single-Domain Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus
M. Nagel
,
Alex Ryder
,
M. Lobbins
,
N. Bhatt
Pediatric Blood & Cancer
2020
Corpus ID: 220500314
To the Editor: Acquired thrombotic thrombocytopenic purpura (aTTP) is a microangiopathic hemolytic anemia with thrombocytopenia…
Expand
Review
2019
Review
2019
Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
M. Mazepa
,
Yara A. Park
,
J. Raval
Transfusion Medicine Reviews
2019
Corpus ID: 201982800
Review
2019
Review
2019
When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP.
Adrien Picod
,
P. Coppo
Transfusion and Apheresis Science
2019
Corpus ID: 131776372
Review
2018
Review
2018
ADAMTS13: origins, applications, and prospects
William E Plautz
,
J. Raval
,
Mitchell R. Dyer
,
M. Rollins-Raval
,
B. Zuckerbraun
,
M. Neal
Transfusion
2018
Corpus ID: 52197893
ADAMTS13 is an enzyme that acts by cleaving prothrombotic von Willebrand factor (VWF) multimers from the vasculature in a highly…
Expand
2018
2018
Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura
F. Peyvandi
,
S. Cataland
,
+9 authors
H. Winter
Blood
2018
Corpus ID: 81244725
Introduction : Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy, in…
Expand
2018
2018
Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules…
J. Hovinga
,
M. Scully
,
+10 authors
A. Metjian
Blood
2018
Corpus ID: 81372079
Introduction : Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy. A…
Expand
Review
2017
Review
2017
Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms.
P. Coppo
Transfusion and Apheresis Science
2017
Corpus ID: 205461607
2016
2016
Convalescent Plasma for Ebola Virus Disease.
T. Fletcher
,
W. Fischer
,
Shevin T. Jacob
New England Journal of Medicine
2016
Corpus ID: 47256626
n engl j med 374;25 nejm.org June 23, 2016 2498 cizumab according to two definitions of refractoriness.2,3 Regardless of the…
Expand
2016
2016
Convalescent Plasma for Ebola Virus Disease.
J. van Griensven
,
T. Edwards
,
P. Gallian
New England Journal of Medicine
2016
Corpus ID: 47256475
n engl j med 374;25 nejm.org June 23, 2016 2498 cizumab according to two definitions of refractoriness.2,3 Regardless of the…
Expand
2014
2014
Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial
F. Peyvandi
,
C. Duby
2014
Corpus ID: 208437622
INTRODUCTION: The TITAN trial achieved its primary endpoint in the ITT analysis of 75 subjects treated either with caplacizumab…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE